Profile data is unavailable for this security.
About the company
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
- Revenue in CAD (TTM)0.00
- Net income in CAD-13.97m
- Incorporated2005
- Employees18.00
- LocationResverlogix Corp300-4820 Richard Rd SWCALGARY T3E 6L1CanadaCAN
- Phone+1 (403) 254-9252
- Fax+1 (403) 254-9252
- Websitehttps://www.resverlogix.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sirona Biochem Corp | -12.09k | -2.31m | 11.56m | -- | -- | -- | -- | -- | -0.0091 | -0.0091 | -0.00005 | -0.012 | -0.0114 | -- | 0.5203 | -- | -218.11 | -173.09 | -- | -383.49 | -- | -- | -- | -1,405.28 | -- | -8.11 | -- | -- | -94.82 | -51.37 | 28.52 | -- | -- | -- |
Medicure Inc | 21.76m | -1.16m | 12.21m | 25.00 | -- | 0.5955 | 12.05 | 0.5611 | -0.1122 | -0.1122 | 2.02 | 1.96 | 0.7499 | 2.52 | 4.11 | 870,400.00 | -4.00 | -13.42 | -5.46 | -18.28 | 64.75 | 61.87 | -5.33 | -27.38 | 1.59 | -- | 0.0227 | -- | -5.94 | -5.71 | -167.55 | -- | -28.82 | -- |
Numinus Wellness Inc | 23.14m | -26.99m | 12.66m | -- | -- | 1.27 | -- | 0.5471 | -0.1022 | -0.1022 | 0.0877 | 0.0315 | 0.7724 | -- | 11.76 | -- | -90.11 | -77.31 | -106.01 | -84.20 | 33.28 | -- | -116.66 | -323.32 | -- | -14.79 | 0.3876 | -- | 256.95 | -- | 32.59 | -- | -- | -- |
Telo Genomics Corp | 0.00 | -2.97m | 14.17m | -- | -- | 22.60 | -- | -- | -0.0434 | -0.0434 | 0.00 | 0.0084 | 0.00 | -- | -- | -- | -323.36 | -85.03 | -407.98 | -113.86 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.66 | -- | 24.41 | -- |
Resverlogix Corp | 0.00 | -13.97m | 15.16m | 18.00 | -- | -- | -- | -- | -0.0542 | -0.0542 | 0.00 | -0.3632 | 0.00 | -- | -- | 0.00 | -133.25 | -- | -- | -- | -- | -- | -- | -- | 0.0359 | -1.10 | -- | -- | -- | -- | -363.74 | -- | -- | -- |
AEterna Zentaris Inc. | 3.24m | -24.62m | 18.98m | 21.00 | -- | 0.4255 | -- | 5.86 | -20.28 | -20.28 | 2.67 | 14.57 | 0.0572 | 1.52 | 6.36 | -- | -43.46 | -26.24 | -50.57 | -30.34 | 90.69 | 83.68 | -760.32 | -300.31 | 5.93 | -- | 0.0177 | -- | -20.25 | -30.06 | 27.17 | -- | 16.12 | -- |
Kane Biotech Inc | 165.60k | -4.94m | 19.12m | -- | -- | -- | -- | 115.44 | -0.0383 | -0.0399 | 0.0013 | -0.089 | 0.0294 | 0.085 | 1.25 | -- | -87.75 | -77.89 | -- | -- | 73.29 | 43.27 | -2,984.41 | -241.85 | 0.2957 | -2.88 | -- | -- | -94.42 | -20.26 | -17.29 | -- | -19.41 | -- |